Trial · NCT00332644
Smoking Cessation Medications: Efficacy, Mechanisms and Algorithms
NCT00332644, Phase 4, Completed, University of Wisconsin, Madison; results first posted 2011-11-30
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Smoking Cessation Medications: Efficacy, Mechanisms and Algorithms. Trials, record NCT00332644. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00332644
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Smoking Cessation Medications: Efficacy, Mechanisms and Algorithms
- NCT number
- NCT00332644
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 1,504 participants, actual
- Lead sponsor
- University of Wisconsin, Madison
- Conditions
- Nicotine Dependence
- Interventions
- nicotine patch, nicotine lozenge, nicotine patch + nicotine lozenge, bupropion, bupropion + lozenge, placebo
- First posted
- 2006-06-02
- Last updated
- 2011-11-30
- Results first posted
- 2011-11-30
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 7-day Point Prevalence of Smoking, Biochemically (Exhaled CO) Confirmed | 6 months post quit date | Smoking status was assessed both as 7-day point-prevalence abstinence ("Have you smoked at all, even a puff, in the last 7 days?") and continuous abstinence (smoking at all since the target quit day), using a smoking calendar and the timeline follow-back method. All participants' self-reports of smoking status during study visits were confirmed by an expired carbon monoxide level of less than 10 ppm measured using a Micro-3 Smokerlyzer (Bedfont Scientific, Williamsburg, Virginia). |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | 7-day Point Prevalence of Smoking, Biochemically (Exhaled CO) Confirmed | 6 months post quit date | participants with<10 ppm exhaled CO | NUMBER |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| 7-day Point Prevalence of Smoking, Biochemically (Exhaled CO) Confirmed | Nicotine Patch | 90 | participants with<10 ppm exhaled CO | ||
| 7-day Point Prevalence of Smoking, Biochemically (Exhaled CO) Confirmed | Nicotine Lozenge | 87 | participants with<10 ppm exhaled CO | ||
| 7-day Point Prevalence of Smoking, Biochemically (Exhaled CO) Confirmed | Nicotine Patch + Lozenge | 107 | participants with<10 ppm exhaled CO | ||
| 7-day Point Prevalence of Smoking, Biochemically (Exhaled CO) Confirmed | Bupropion | 84 | participants with<10 ppm exhaled CO | ||
| 7-day Point Prevalence of Smoking, Biochemically (Exhaled CO) Confirmed | Bupropion + Nicotine Lozenge | 87 | participants with<10 ppm exhaled CO | ||
| 7-day Point Prevalence of Smoking, Biochemically (Exhaled CO) Confirmed | Placebo Control | 42 | participants with<10 ppm exhaled CO |
Source ClinicalTrials.gov
Participant flow18
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Nicotine Patch | 262 | |
| Overall Study | STARTED | Nicotine Lozenge | 260 | |
| Overall Study | STARTED | Nicotine Patch + Lozenge | 267 | |
| Overall Study | STARTED | Bupropion | 264 | |
| Overall Study | STARTED | Bupropion + Nicotine Lozenge | 262 | |
| Overall Study | STARTED | Placebo Control | 189 | |
| Overall Study | COMPLETED | Nicotine Patch | 250 | |
| Overall Study | COMPLETED | Nicotine Lozenge | 238 | |
| Overall Study | COMPLETED | Nicotine Patch + Lozenge | 258 | |
| Overall Study | COMPLETED | Bupropion | 244 |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 participant flowAdverse events132
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | cold | Infections and infestations | Nicotine Patch | 92 | 262 | 92 |
| other | cold | Infections and infestations | Nicotine Lozenge | 102 | 260 | 102 |
| other | cold | Infections and infestations | Nicotine Patch + Lozenge | 88 | 267 | 88 |
| other | cold | Infections and infestations | Bupropion | 74 | 264 | 74 |
| other | cold | Infections and infestations | Bupropion + Nicotine Lozenge | 65 | 262 | 65 |
| other | cold | Infections and infestations | Placebo Control | 57 | 189 | 57 |
| other | cough | Infections and infestations | Nicotine Patch | 16 | 262 | 16 |
| other | cough | Infections and infestations | Nicotine Lozenge | 13 | 260 | 13 |
| other | cough | Infections and infestations | Nicotine Patch + Lozenge | 13 | 267 | 13 |
| other | cough | Infections and infestations | Bupropion | 9 | 264 | 9 |
1 to 10 of 132Source ClinicalTrials.gov
See all 132 adverse eventsAdverse event totals18
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Nicotine Patch | ||
| Total, all-cause mortality | Nicotine Lozenge | ||
| Total, all-cause mortality | Nicotine Patch + Lozenge | ||
| Total, all-cause mortality | Bupropion | ||
| Total, all-cause mortality | Bupropion + Nicotine Lozenge | ||
| Total, all-cause mortality | Placebo Control | ||
| Total, other adverse events | Nicotine Patch | 207 | 262 |
| Total, other adverse events | Nicotine Lozenge | 214 | 260 |
| Total, other adverse events | Nicotine Patch + Lozenge | 227 | 267 |
| Total, other adverse events | Bupropion | 195 | 264 |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 adverse event totalsPapers10
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P50DA019706 | Tobacco Dependence: Treatment and Outcomes | BAKER, TIMOTHY B | UNIVERSITY OF WISCONSIN-MADISON | NATIONAL INSTITUTE ON DRUG ABUSE | 2004 to 2008 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00332644
GET https://conductscience.org/api/trials/v1/NCT00332644/events?page=2